| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Sara Nik downgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Neutral.
Needham analyst Joseph Stringer downgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Hold.
Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.